Variations and trends in global disease burden of age‐related macular degeneration: 1990‐2017

Zou, Minjie; Zhang, Yichi; Chen, Aiming; Young, Charlotte Aimee; Li, Yang; Zheng, Danying; Jin, Guangming

doi:10.1111/aos.14589

Cited by 21 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SDI is a summary index that can be used to represent the position of a nation on the spectrum of economic development, and different regions in each nation can have significantly different SDI levels (39). A previous study has reported the AMD burden to be higher in low SDI regions (40). However, this study showed that the middle SDI regions demonstrated the highest number of AMD cases and YLDs, and the low SDI region demonstrated the lowest.…”

Section: Discussioncontrasting

confidence: 68%

Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019

Jiang

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

ObjectivesThis study aims to estimate the trends and disparities in the worldwide burden for health of AMD, overall and by age, sex, socio-demographic index (SDI), region, and nation using prevalence and years lived with disability (YLDs) from Global Burden of Disease (GBD) study 2019.MethodsThis retrospective study presents the prevalent AMD cases and YLDs from 1990–2019, as well as the age-standardized prevalence rate (ASPR) and age-standardized YLD rate (ASYR) of AMD. To measure changes over time, estimated annual percentage changes (EAPCs) of the age-standardized rates (ASRs) were analyzed globally, then studied further by sex, SDI, region, and nation. We included data from the 2019 Global Burden of Disease (GBD) database to examine AMD prevalence and YLDs from 1990–2019 in 204 countries and territories, as well as demographic information such as age, sex, SDI, region, and nation.ResultsGlobally, the number of prevalent AMD cases increased from 3,581,329.17 (95% uncertainty interval [UI], 3,025,619.4–4,188,835.7) in 1990 to 7,792,530 (95% UI, 6,526,081.5–9,159,394.9) in 2019, and the number of YLDs increased from 296,771.93 (95% uncertainty interval [UI], 205,462.8–418,699.82) in 1990 to 564,055.1 (95% UI, 392,930.7–789,194.64) in 2019. The ASPR of AMD had a decreased trend with an EAPC of −0.15 (95% confidence interval [CI], −0.2 to −0.11) from 1990 to 2019, and the ASYR of AMD showed a decreased trend with an EAPC of −0.71 (95% confidence interval [CI], −0.78 to −0.65) during this period. The prevalence and YLDs of AMD in adults over 50 years of age showed a significant increase. The prevalence and YLDs of AMD were significantly higher in females than males, overall. The ASPRs and ASYRs in low SDI regions was greater than in high SDI regions from 1990 to 2019. In addition, increases in prevalence and YLDs differed by regions and nations, as well as level of socio-economic development.ConclusionThe number of prevalent cases and YLDs due to AMD increased over 30 years and were directly linked to age, sex, socio-economic status, and geographic location. These findings can not only guide public health work but also provide an epidemiological basis for global strategy formulation regarding this global health challenge.

show abstract

Section: Discussioncontrasting

confidence: 68%

Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019

Jiang

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Kruskal–Wallis H-test was conducted to assess the difference in age-standardized DALY rates across HDI-based categories, followed by Mann–Whitney U-test for post-hoc pairwise comparisons. Stepwise multiple linear regression analysis was conducted to explore the associations between the age-standardized DALY rates of CKD due to hypertension and country-level demographic and socioeconomic factors; commonly used country-level indexes were selected as potential associated factors with CKD attributable to hypertension based on previous published studies ( 23 , 24 , 26 ) and variables at a level of p ≤ 0.2 were selected for inclusion in multiple stepwise regression analysis for further analysis. All statistical analyses were performed by using Stata MP 15.0 (Stata Corp LP, College Station, Texas, USA).…”

Section: Methodsmentioning

confidence: 99%

“…According to published GBD studies on different chronic diseases (22)(23)(24), different country-level demographic and socioeconomic factors were selected from open databases to investigate their correlations with disease burden of CKD due to hypertension. Socio-demographic index (SDI), a composite index reflecting a country's socio-demographic development status, was also extracted from the GHDx (http://ghdx.healthdata.org, accessed 10 Nov 2019).…”

Section: Selection Of Country-level Factorsmentioning

confidence: 99%

Disease Burden of Chronic Kidney Disease Due to Hypertension From 1990 to 2019: A Global Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Although it is widely known that hypertension is an important cause of chronic kidney disease (CKD), little detailed quantitative research exists on the burden of CKD due to hypertension.Objective: The objective of the study is to estimate the global disease burden of CKD due to hypertension and to evaluate the association between the socioeconomic factors and country-level disease burden of CKD due to hypertension.Methods: We extracted the disability-adjusted life-year (DALY) numbers, rates, and age-standardized rates of CKD due to hypertension from the Global Burden of Disease Study 2019 database to investigate the time trends of the burden of CKD due to hypertension from 1990 to 2019. Stepwise multiple linear regression analysis was performed to evaluate the correlations between the age-standardized DALY rate and socioeconomic factors and other related factors obtained from open databases.Results: Globally, from 1990 to 2019, DALY numbers caused by CKD due to hypertension increased by 125.2% [95% confidential interval (CI), 124.6 to 125.7%]. The DALY rate increased by 55.7% (55.3 to 56.0%) to 128.8 (110.9 to 149.2) per 100,000 population, while the age-standardized DALYs per 100,000 population increased by 10.9% (10.3 to 11.5%). In general, males and elderly people tended to have a higher disease burden. The distribution disparity in the burden of CKD due to hypertension varies greatly among countries. In the stepwise multiple linear regression model, inequality-adjusted human development index (IHDI) [β = −161.1 (95% CI −238.1 to −84.2), P < 0.001] and number of physicians per 10,000 people [β = −2.91 (95% CI −4.02 to −1.80), P < 0.001] were significantly negatively correlated with age-standardized DALY rate when adjusted for IHDI, health access and quality (HAQ), number of physicians per 10,000 people, and population with at least some secondary education.Conclusion: Improving the average achievements and equality of distribution in health, education, and income, as well as increasing the number of physicians per 10,000 people could help to reduce the burden of CKD due to hypertension. These findings may provide relevant information toward efforts to optimize health policies aimed at reducing the burden of CKD due to hypertension.

show abstract

“…(5) Inhibition of pyroptosis; (6) Inhibition of carbonyl stress; (7) Inhibition of G 2 /M phase arrest; (8) Inhibition of VEGF activation.…”

Section: Nutritional Treatmentmentioning

confidence: 99%

“…Among those aged 80 years and above, 66% have several signs of AMD [ 4 , 5 ], and 3% of those over 65 years old suffer visual problems caused by AMD [ 6 ]. According to Zou’s study on the global burden of AMD from 1990 to 2017, special groups can significantly suffer from AMD, such as females, the elderly, those from developing countries, and low-educated persons, etc., and from 1990 to 2017, AMD contributed to a doubling of the number of people living a low quality of life [ 7 ]. An even more serious consideration is that the number of global AMD patients has been predicted to rise from 196 million in 2020 to 288 million in 2040 [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Medication Trends for Age-Related Macular Degeneration

Cho

Park

Jeon

2021

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is central vision loss with aging, was the fourth main cause of blindness in 2015, and has many risk factors, such as cataract surgery, cigarette smoking, family history, hypertension, obesity, long-term smart device usage, etc. AMD is classified into three categories: normal AMD, early AMD, and late AMD, based on angiogenesis in the retina, and can be determined by bis-retinoid N-retinyl-N-retinylidene ethanolamine (A2E)-epoxides from the reaction of A2E and blue light. During the reaction of A2E and blue light, reactive oxygen species (ROS) are synthesized, which gather inflammatory factors, induce carbonyl stress, and finally stimulate the death of retinal pigment epitheliums (RPEs). There are several medications for AMD, such as device-based therapy, anti-inflammatory drugs, anti-VEGFs, and natural products. For device-based therapy, two methods are used: prophylactic laser therapy (photocoagulation laser therapy) and photodynamic therapy. Anti-inflammatory drugs consist of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). Anti-VEGFs are classified antibodies for VEGF, aptamer, soluble receptor, VEGF receptor-1 and -2 antibody, and VEGF receptor tyrosine kinase inhibitor. Finally, additional AMD drug candidates are derived from natural products. For each medication, there are several and severe adverse effects, but natural products have a potency as AMD drugs, as they have been used as culinary materials and/or traditional medicines for a long time. Their major application route is oral administration, and they can be combined with device-based therapy, anti-inflammatory drugs, and anti-VEGFs. In general, AMD drug candidates from natural products are more effective at treating early and intermediate AMD. However, further study is needed to evaluate their efficacy and to investigate their therapeutic mechanisms.

show abstract

Variations and trends in global disease burden of age‐related macular degeneration: 1990‐2017

Cited by 21 publications

References 23 publications

Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019

Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019

Disease Burden of Chronic Kidney Disease Due to Hypertension From 1990 to 2019: A Global Analysis

Medication Trends for Age-Related Macular Degeneration

Contact Info

Product

Resources

About